Brief Introduction

BrightGene Bio-Medical Technology Co., Ltd. Is founded in 2001, The company is a research driven and technology platform-based enterprise, engages in international competition of the whole industry chain of chemical drugs, and has formed continuous profit model covering the whole industry chain including “starting materials-intermediates with high technical difficulty-distinctive APIs-drug products”.

BrightGene has its innovation pipeline including antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); high-end generic drugs mainly include: generic drugs which are difficult to synthesize, semi-synthetic fermentation products, biosimilars and special drug delivery systems (DDS) such as nanoemulsions.

Aim at regulated market, BrightGene has cGMP compliance factories, and has got approval from USFDA, EU, PMDA, KFDA and CFDA.

BrightGene has exceptional R&D capability and robust project execution. Combining high productivity and cost-effective resources, along with unmatched regulatory and technical know-how, BrightGene is uniquely positioned to compete in the global pharmaceutical industry, particularly the fast growing specialty pharmaceutical sector.

Company Overview

Full name BrightGene Bio-Medical Technology Co.,Ltd.
Abbreviations BrightGene
Code 688166
Founded 2001.10.26
Listing 2019.11.08
Domicile Suzhou
STAR Theme Biomedicine
CSRCSector Manufacturing
Has weighted voting rights structure? No



  2018 2017 2016
Earnings Per Share 0.21 0.14 0.06
R&D expenditure as a % of operating revenue 23.59% 25.51% 26.67%
Operating Revenue 408M 317M 201M
Net Income 73M 46M 17M

Income Statement (Unit: RMB mn)

  2018 2017 2016
Operating Revenue 408 317 201
Operating Costs 324 267 184
Operating Income 82 49 16
Pretax Income 79 49 19
Income Tax 6 3 2
Net Income 73 46 17

Balance Sheet(Unit: RMB mn)

  2018 2017 2016
Current Assets-Total 563 300 209
Non-current Assets-Total 312 225 175
Total Assets 875 525 384
Current Liabilities-Total 106 79 164
Non-current Liabilities-Total 0 0 0
Total Liabilities 106 79 164
Stockholder's Equity
Share Capital 671 421 241
Retained Profits 99 25 -21
Total Owners' Equity 770 446 220

Cash Flow Statement (Unit: RMB mn)

  2018 2017 2016
Net Cash Flows-Operating 64 36 30
Net Cash Flows-Investing -212 -81 -37
Net Cash Flows-Financing 250 110 12

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
Jiandong Yuan 113.53 27.69%
Weifang Zhong 39.19 9.56%
苏州博瑞鑫稳管理咨询合伙企业(有限合伙) 35.25 8.60%
宁波梅山保税港区红杉智盛股权投资合伙企业(有限合伙) 28.72 7.01%
先进制造产业投资基金(有限合伙) 18.61 4.54%
宁波保税区弘鹏股权投资合伙企业(有限合伙) 13.11 3.20%
南京华泰大健康一号股权投资合伙企业(有限合伙) 12.85 3.14%
广发乾和投资有限公司 9.15 2.23%
中金佳泰(天津)股权投资基金合伙企业(有限合伙) 8.01 1.95%
苏州高铨创业投资企业(有限合伙) 7.82 1.91%
08 Nov 2019

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.